Suppressing CD33 stimulates phagocytosis, slows plaque growth. A protective CD33 mutation could be a gain of function that activates phagocytosis. The CD33 receptor acts as a dimer. At the 14th ...

Acute myeloid leukemia (AML) is one of the most common forms of cancer in children and adults. CD33, a protein often expressed on the surface of leukemic cells, has been a long-standing target for AML ...

SAN CARLOS, Calif., Nov. 19, 2025 /PRNewswire/ -- Aperture Therapeutics, a biotechnology company pioneering next-generation precision medicines for neurodegenerative diseases, today announced the ...

SAN FRANCISCO, CA--(Marketwired - Jun 1, 2015) - Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, today announced positive data from several preclinical studies characterizing the ...

Digital Fusion-Gene expression profiling in acute leukemia (AL): Clinical validation of throughput molecular technology in laboratory medicine. Long-term bosutinib (BOS) for Philadelphia ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced an exclusive licensing ...

NEW YORK--(BUSINESS WIRE)--iCell Gene Therapeutics, LLC announced results from a study ongoing at Chengdu Military General Hospital of ICG144, the first CLL1-CD33 Compound CAR T-cell (cCAR) in ...

M2T-CD33 has received orphan drug designation for AML, offering incentives like tax credits and market exclusivity. The M2T platform is a novel immunotherapy approach targeting CD33-positive leukemic ...

Antibody-based therapeutics are valuable tools for the treatment of many human diseases. For example, antibody-based immunotherapies targeting the leukemia antigens CD19 and CD20 have been remarkably ...

SAN FRANCISCO, CA--(Marketwired - Aug 10, 2016) - Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted an ...